Exploring determinants of psoriasis patients’ treatment choices: a discrete-choice experiment study in the United States and Germany

Steven R. Feldman; Christine Poulos; Isabelle Gilloteau; Brennan Mange; Katharina Boehm; Marco Boeri; Mandy Naatz; Matthias Augustin

doi:10.1080/09546634.2020.1839007

Exploring determinants of psoriasis patients’ treatment choices: a discrete-choice experiment study in the United States and Germany

Steven R. Feldman, Christine Poulos^*, Isabelle Gilloteau, Brennan Mange, Katharina Boehm, Marco Boeri, Mandy Naatz, Matthias Augustin

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

38 Downloads (Pure)

Abstract

Background: Biologic psoriasis treatments are differentiated by efficacy, side effects, and other attributes. Objective: Determine attributes of biologic psoriasis treatments that drive patients’ treatment choices. Methods: Respondents (USA: n = 300; Germany: n = 300) with moderate-to-severe psoriasis completed a discrete-choice–experiment survey, choosing between hypothetical treatments characterized by attributes with varying levels: chance of clear skin after 1 year, number of first-year treatments, first-year risks of mild-to-moderate injection site reaction (ISR) and serious infection, and years of proven efficacy/safety. Results: U.S. respondents most valued clear skin (conditional relative importance, 1.88; p <.05). While other attributes were of generally equivalent importance, ISR risk outweighed serious-infection risk (1.06 vs. 0.70; p <.05). German respondents placed greatest importance on ISR risk (1.61; p <.05) and clear skin (1.49; p <.05). Limitations: Respondents evaluated hypothetical treatments and were recruited from web panels. Conclusions: Clear skin and ISR risk are stronger drivers of treatment choice than injection frequency and infection risk.

Original language	English
Number of pages	11
Journal	Journal of Dermatological Treatment
Early online date	03 Feb 2021
DOIs	https://doi.org/10.1080/09546634.2020.1839007
Publication status	Early online date - 03 Feb 2021
Externally published	Yes

Bibliographical note

Funding Information:
This study was performed under a research contract between RTI Health Solutions and Novartis Pharma A/G and was funded by Novartis Pharma A/G. IG and KB are salaried employees of Novartis. CP, BM, and MB are salaried employees of RTI Health Solutions. MA has received consulting or lecturing fees and/or research grants from AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Celgene Corporation, Centocor, Eli Lilly, GSK, Janssen-Cilag, LEO Pharma, Medac, Merck, MSD, Novartis, Pfizer, UCB, and XenoPort. MG has received consulting fees and/or travel expenses from Astellas Pharma, Lilly and Novartis Pharma. SF has received research, speaking, and/or consulting support from a variety of companies, including Novartis, Galderma, GSK/Stiefel, Leo Pharma, Baxter, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Valeant, AbbVie, Cosmederm, Anacor, Astellas, Janssen, Lilly, Merck, Merz, Qurient, National Biological Corporation, Caremark, Advance Medical, Suncare Research, Informa, UpToDate, and the National Psoriasis Foundation. He is founder and majority owner of www.DrScore.com , a patient satisfaction survey service, and is a founder and part owner of Causa Research, a company working to enhance patients’ adherence to treatment.

Publisher Copyright:
© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.

Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.

Keywords

discrete-choice experiment
patient
preference
Psoriasis

ASJC Scopus subject areas

Dermatology

Access to Document

10.1080/09546634.2020.1839007Licence: CC BY-NC-ND

Exploring determinants of psoriasis patients’ treatment choices: a discretechoice experiment study in the United States and Germany
Copyright 2021 the authors. This is an open access article published under a Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited.
Final published version, 1.55 MBLicence: CC BY-NC-ND

Cite this

@article{0a13fbf43ba0468696a4ad32677cf848,

title = "Exploring determinants of psoriasis patients{\textquoteright} treatment choices: a discrete-choice experiment study in the United States and Germany",

abstract = "Background: Biologic psoriasis treatments are differentiated by efficacy, side effects, and other attributes. Objective: Determine attributes of biologic psoriasis treatments that drive patients{\textquoteright} treatment choices. Methods: Respondents (USA: n = 300; Germany: n = 300) with moderate-to-severe psoriasis completed a discrete-choice–experiment survey, choosing between hypothetical treatments characterized by attributes with varying levels: chance of clear skin after 1 year, number of first-year treatments, first-year risks of mild-to-moderate injection site reaction (ISR) and serious infection, and years of proven efficacy/safety. Results: U.S. respondents most valued clear skin (conditional relative importance, 1.88; p <.05). While other attributes were of generally equivalent importance, ISR risk outweighed serious-infection risk (1.06 vs. 0.70; p <.05). German respondents placed greatest importance on ISR risk (1.61; p <.05) and clear skin (1.49; p <.05). Limitations: Respondents evaluated hypothetical treatments and were recruited from web panels. Conclusions: Clear skin and ISR risk are stronger drivers of treatment choice than injection frequency and infection risk.",

keywords = "discrete-choice experiment, patient, preference, Psoriasis",

author = "Feldman, {Steven R.} and Christine Poulos and Isabelle Gilloteau and Brennan Mange and Katharina Boehm and Marco Boeri and Mandy Naatz and Matthias Augustin",

note = "Funding Information: This study was performed under a research contract between RTI Health Solutions and Novartis Pharma A/G and was funded by Novartis Pharma A/G. IG and KB are salaried employees of Novartis. CP, BM, and MB are salaried employees of RTI Health Solutions. MA has received consulting or lecturing fees and/or research grants from AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Celgene Corporation, Centocor, Eli Lilly, GSK, Janssen-Cilag, LEO Pharma, Medac, Merck, MSD, Novartis, Pfizer, UCB, and XenoPort. MG has received consulting fees and/or travel expenses from Astellas Pharma, Lilly and Novartis Pharma. SF has received research, speaking, and/or consulting support from a variety of companies, including Novartis, Galderma, GSK/Stiefel, Leo Pharma, Baxter, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Valeant, AbbVie, Cosmederm, Anacor, Astellas, Janssen, Lilly, Merck, Merz, Qurient, National Biological Corporation, Caremark, Advance Medical, Suncare Research, Informa, UpToDate, and the National Psoriasis Foundation. He is founder and majority owner of www.DrScore.com , a patient satisfaction survey service, and is a founder and part owner of Causa Research, a company working to enhance patients{\textquoteright} adherence to treatment. Publisher Copyright: {\textcopyright} 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = feb,

day = "3",

doi = "10.1080/09546634.2020.1839007",

language = "English",

journal = "Journal of Dermatological Treatment",

issn = "0954-6634",

publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Exploring determinants of psoriasis patients’ treatment choices: a discrete-choice experiment study in the United States and Germany

AU - Feldman, Steven R.

AU - Poulos, Christine

AU - Gilloteau, Isabelle

AU - Mange, Brennan

AU - Boehm, Katharina

AU - Boeri, Marco

AU - Naatz, Mandy

AU - Augustin, Matthias

N1 - Funding Information: This study was performed under a research contract between RTI Health Solutions and Novartis Pharma A/G and was funded by Novartis Pharma A/G. IG and KB are salaried employees of Novartis. CP, BM, and MB are salaried employees of RTI Health Solutions. MA has received consulting or lecturing fees and/or research grants from AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Celgene Corporation, Centocor, Eli Lilly, GSK, Janssen-Cilag, LEO Pharma, Medac, Merck, MSD, Novartis, Pfizer, UCB, and XenoPort. MG has received consulting fees and/or travel expenses from Astellas Pharma, Lilly and Novartis Pharma. SF has received research, speaking, and/or consulting support from a variety of companies, including Novartis, Galderma, GSK/Stiefel, Leo Pharma, Baxter, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Valeant, AbbVie, Cosmederm, Anacor, Astellas, Janssen, Lilly, Merck, Merz, Qurient, National Biological Corporation, Caremark, Advance Medical, Suncare Research, Informa, UpToDate, and the National Psoriasis Foundation. He is founder and majority owner of www.DrScore.com , a patient satisfaction survey service, and is a founder and part owner of Causa Research, a company working to enhance patients’ adherence to treatment. Publisher Copyright: © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/2/3

Y1 - 2021/2/3

N2 - Background: Biologic psoriasis treatments are differentiated by efficacy, side effects, and other attributes. Objective: Determine attributes of biologic psoriasis treatments that drive patients’ treatment choices. Methods: Respondents (USA: n = 300; Germany: n = 300) with moderate-to-severe psoriasis completed a discrete-choice–experiment survey, choosing between hypothetical treatments characterized by attributes with varying levels: chance of clear skin after 1 year, number of first-year treatments, first-year risks of mild-to-moderate injection site reaction (ISR) and serious infection, and years of proven efficacy/safety. Results: U.S. respondents most valued clear skin (conditional relative importance, 1.88; p <.05). While other attributes were of generally equivalent importance, ISR risk outweighed serious-infection risk (1.06 vs. 0.70; p <.05). German respondents placed greatest importance on ISR risk (1.61; p <.05) and clear skin (1.49; p <.05). Limitations: Respondents evaluated hypothetical treatments and were recruited from web panels. Conclusions: Clear skin and ISR risk are stronger drivers of treatment choice than injection frequency and infection risk.

AB - Background: Biologic psoriasis treatments are differentiated by efficacy, side effects, and other attributes. Objective: Determine attributes of biologic psoriasis treatments that drive patients’ treatment choices. Methods: Respondents (USA: n = 300; Germany: n = 300) with moderate-to-severe psoriasis completed a discrete-choice–experiment survey, choosing between hypothetical treatments characterized by attributes with varying levels: chance of clear skin after 1 year, number of first-year treatments, first-year risks of mild-to-moderate injection site reaction (ISR) and serious infection, and years of proven efficacy/safety. Results: U.S. respondents most valued clear skin (conditional relative importance, 1.88; p <.05). While other attributes were of generally equivalent importance, ISR risk outweighed serious-infection risk (1.06 vs. 0.70; p <.05). German respondents placed greatest importance on ISR risk (1.61; p <.05) and clear skin (1.49; p <.05). Limitations: Respondents evaluated hypothetical treatments and were recruited from web panels. Conclusions: Clear skin and ISR risk are stronger drivers of treatment choice than injection frequency and infection risk.

KW - discrete-choice experiment

KW - patient

KW - preference

KW - Psoriasis

U2 - 10.1080/09546634.2020.1839007

DO - 10.1080/09546634.2020.1839007

M3 - Article

AN - SCOPUS:85100616029

JO - Journal of Dermatological Treatment

JF - Journal of Dermatological Treatment

SN - 0954-6634

ER -

Exploring determinants of psoriasis patients’ treatment choices: a discrete-choice experiment study in the United States and Germany

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this